Last reviewed · How we verify
Drug Eluting Bead Transarterial Chemoembolization
At a glance
| Generic name | Drug Eluting Bead Transarterial Chemoembolization |
|---|---|
| Also known as | deb-TACE |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Abdominal pain
- Pruritus
- Rash maculo-papular
- Diarrhea
- Edema limbs
- Anorexia
- Fever
- Hyperthyroidism
- Aspartate aminotransferase increased
- Blood bilirubin increased
- Constipation
Key clinical trials
- IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (PHASE2)
- Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (PHASE3)
- TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens (PHASE2)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma (PHASE2, PHASE3)
- Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
- Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
- DEB-TACE vs cTACE in HCC After TIPS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: